As expected, combinational treatment of morusin and TMZ dramatically induced the expression of p-eIF2a and CHOP (Figure 6E,F), which seemed to be a key factor in the synergistic cytotoxicity against GBM cells. The gene discussed is DDIT3; the disease is glioblastoma.